Alcon & Origenis intensify relationship
German firm Origenis has extended its research alliance with Alcon Research, to develop small molecule drugs against important ophthalmic targets, for two years.
Origenis' MOREsystem enables the directed target and indication optimized exploitation of billions of novel compounds through a proprietary multiparametric optimization process. Origenis will apply this platform to deliver preclinical candidates with indication optimized profiles for certain Alcon targets. Alcon, in turn, will bring its applied biology expertise, screening capabilities and development proficiency to the alliance.
Under the terms of the agreement, Alcon will retain the rights to any ophthalmic or nasal applications developed and will make research payments to Origenis through a series of development milestones and royalties on sales. Origenis will retain certain rights to all other uses of drug candidates discovered during the alliance.